Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
Markets Open Last Week of Q2 in the Red as Tech Stocks Slide
05:00pm, Monday, 26'th Jun 2023
Markets Open Last Week of Q2 on Monday, June 26 in the Red as Tech Stocks Slide.
Trial anticipation for weight loss drugs shows they will be popular, says Dr. Kavita Patel
03:30pm, Monday, 26'th Jun 2023
Dr. Kavita Patel, NBC News medical contributor, joins 'Power Lunch' to discuss the anticipation for weight loss drugs.
Weight-loss drugs in development aim to replace injections with pills
03:21pm, Monday, 26'th Jun 2023
Wall Street's obsession with next-generation obesity and diabetes treatments intensified over the weekend as drugmakers presented new clinical-trial data on the drugs — including weight-loss pills i
Pfizer Shares Slide After Ending Study of Obesity Drug
12:55pm, Monday, 26'th Jun 2023
Pfizer shares fell after ending development of an oral treatment for obesity and diabetes.
Why Pfizer Stock Is Tanking Today
11:20am, Monday, 26'th Jun 2023
Pfizer is discontinuing the development of an early-stage weight loss candidate over safety concerns. As a result of the drug's enormous commercial potential, Pfizer's shares are taking a step backwar
Pfizer's (PFE) Litfulo Receives FDA Nod for Alopecia Areata
09:46am, Monday, 26'th Jun 2023
Pfizer's (PFE) Litfulo becomes the first kinase inhibitor approved for treating severe alopecia areata in adolescents, following FDA's approval.
Pfizer to end development of experimental obesity pill due to elevated liver enzymes
08:35am, Monday, 26'th Jun 2023
Pfizer's two pills are part of the same class of obesity drugs as Novo Nordisk's blockbuster weight loss injections Ozempic and Wegovy.
3 Stocks to Buy for Long-Term Dividends and Buybacks
08:13am, Monday, 26'th Jun 2023
Income investors often search for stocks for long-term dividends and buybacks to round out their portfolios. The obvious starting point to locate these types of investments is by looking at yield.
Pfizer to discontinue development of obesity drug
07:03am, Monday, 26'th Jun 2023
Pfizer Inc said on Monday it is discontinuing the development of an experimental obesity and diabetes drug, lotiglipron, due to elevated liver enzymes in patients in clinical studies.
Affordable Blue-Chips: 3 High-Potential Stocks With Low P/E Ratios
06:04am, Monday, 26'th Jun 2023
It's not easy to find affordable blue-chip stocks from a valuation perspective. Since these stocks represent fundamentally strong business stories, there is a valuation premium attached.
500 Top Dividend Dogs
09:17am, Sunday, 25'th Jun 2023
The June/July 2023 edition of Fortune Magazine revealed 500 biggest U.S. companies by revenue. To sniff out the best dividend buys, I focused on 68 industry leaders using YCharts 6/22/23 data. Those 6
US FDA approves Pfizer's hair loss drug
06:19pm, Friday, 23'rd Jun 2023
The U.S. Food and Drug Administration has approved Pfizer Inc's drug to treat hair loss caused by an autoimmune disease, the company said on Friday.
Pfizer's alopecia drug for teens and adults approved by FDA
06:02pm, Friday, 23'rd Jun 2023
Pfizer Inc. PFE, -1.11% said late Friday that its drug ritlecitinib, sold under the brand name of Litfulo, has been approved by the U.S. Food and Drug Administration to treat adults and teens sufferin
Pfizer/BioNTech initiate application with EU regulator for updated COVID vaccine
05:19pm, Friday, 23'rd Jun 2023
Pfizer and partner BioNTech said on Friday they have initiated an application to the European Medicines Agency (EMA) for authorization of updated COVID-19 vaccine targeting Omicron subvariant XBB.1.5.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
10:24am, Friday, 23'rd Jun 2023
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
